Techniclone to Obtain License for Antibody
- Share via
Dow Jones
Techniclone Corp. said Thursday that it will exercise its option to obtain the license for an anti-angiogenesis antibody, 2C3, and its derivatives from the University of Texas Southwestern Medical Center in Dallas.
The Tustin biopharmaceutical company, which develops cancer treatments, said in a press release that the antibody can inhibit tumor vessel growth.
Techniclone will obtain all the antibody rights and pay all patent costs, completing the license agreement with the university.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
